POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.194
https://www.valueinhealthjournal.com/article/S1098-3015(21)01989-6/fulltext
Title :
POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)01989-6&doi=10.1016/j.jval.2021.11.194
First page :
Section Title :
Open access? :
No
Section Order :
10966